# Detection and characterization of complex rearrangements in tumor genomes

Aaron Quinlan quinlanlab.org

BioConductor 2013, Seattle WA, July 18, 2013



University of Virginia, Charlottesville VA Center for Public Health Genomics Biochemistry and Molecular Genetics



Thursday, July 25, 13

## SV definitions





**structural variant (SV)**: a difference in the copy number, orientation or location of genomic segments >100bp

genomic rearrangement: ditto

**copy number variant (CNV), or alteration (CNA)**: an SV that alters DNA copy number

**breakpoint**: The junction(s) between structurally variable genomic segments

**complex SV**: 2 or more breakpoints that arise through a single mutational event, but cannot be explained by one DNA exchange or end-joining reaction

### "Signals" for SV discovery







 Prior knowledge
New signals (e.g. positional seq.)
Known SV sites
Predictions from other tools

Most existing SV tools exploit just one signal

 Most current datasets have low to moderate physical coverage due to small insert size (~10-20X)

- Most current datasets have low to moderate physical coverage due to small insert size (~10-20X)
- Breakpoints are enriched in repetitive genomic regions that pose problems for sensitive read alignment

- Most current datasets have low to moderate physical coverage due to small insert size (~10-20X)
- Breakpoints are enriched in repetitive genomic regions that pose problems for sensitive read alignment
- Filtering false positives also eliminates true positives.

- Most current datasets have low to moderate physical coverage due to small insert size (~10-20X)
- Breakpoints are enriched in repetitive genomic regions that pose problems for sensitive read alignment
- Filtering false positives also eliminates true positives.
- The false negative rate is usually hard to measure, but is thought to be extremely high for most PEM studies (>30%)

- Most current datasets have low to moderate physical coverage due to small insert size (~10-20X)
- Breakpoints are enriched in repetitive genomic regions that pose problems for sensitive read alignment
- Filtering false positives also eliminates true positives.
- The false negative rate is usually hard to measure, but is thought to be extremely high for most PEM studies (>30%)
- When searching for somatic mutation in a tumor/normal comparison, a false negative call in the normal can cause a false positive somatic call in the tumor.

- Most current datasets have low to moderate physical coverage due to small insert size (~10-20X)
- Breakpoints are enriched in repetitive genomic regions that pose problems for sensitive read alignment
- Filtering false positives also eliminates true positives.
- The false negative rate is usually hard to measure, but is thought to be extremely high for most PEM studies (>30%)
- When searching for somatic mutation in a tumor/normal comparison, a false negative call in the normal can cause a false positive somatic call in the tumor.
- False negatives are very problematic in the context of tumor heterogeneity

A probabilistic framework that integrates multiple alignment "signals" for SV discovery. *Improved sensitivity.* 

under review

### **DELLY:** Rausch et al, 2012



### GASVPro: Sindhi et al, 2012



Combines DoC and PEM signals for greater specificity, especially for deletions (using DoC) "Integrative" Known SV sites Predictions from other tools





 Prior knowledge
New signals (e.g. positional seq.)
Known SV sites
Predictions from other tools

LUMPY integrates all (and future) signals

# LUMPY integrates all SV signals









DNA library fragment size distribution (~500bp library)



When aligned to reference, ends map ~1500bp apart. Where are the breakpoints?



When aligned to reference, ends map ~1500bp apart. Where are the breakpoints?





When aligned to reference, ends map ~1500bp apart. Where are the breakpoints?





When aligned to reference, ends map ~1500bp apart. Where are the breakpoints?





When aligned to reference, ends map ~1500bp apart. Where are the breakpoints?























Much greater SV breakpoint resolution and sensitivity

# Sensitivity is crucial in the context of tumor heterogeneity



Russnes et al, 2011

#### Tumor heterogeneity simulation: an in silico "spike in"



#### Tumor heterogeneity simulation: an in silico "spike in"





#### Tumor heterogeneity simulation: an in silico "spike in"



### LUMPY has highest sensitivity





### LUMPY has highest sensitivity...with minimal FDR



### The impact of combining multiple SV signals

Combining paired-end and split-read signals is more sensitive than each alone

(40X coverage)



# Solution 2: pool data from many samples

It improves SNP and INDEL calling, so why not SVs?

Thursday, July 25, 13

# PEM clusters discordant mappings



### **HYDRA-MULTI**: Pooling prevents false somatic calls



#### Quinlan et al., Cell Stem Cell (2011);

**Note**: GATK pioneered population-based SNP and INDEL detection; GenomeSTRiP and VariationHunter use a similar approach Thursday, July 25, 13

# The landscape of complex variation in 64 cancer genomes. (using HYDRA-MULTI)

### Breakpoint profiling of 64 cancer genomes reveals numerous complex rearrangements spawned by homology-independent mechanisms

Ankit Malhotra,<sup>1</sup> Michael Lindberg,<sup>1</sup> Gregory G. Faust,<sup>1,2</sup> Mitchell L. Leibowitz,<sup>1</sup> Royden A. Clark,<sup>1</sup> Ryan M. Layer,<sup>1,2</sup> Aaron R. Quinlan,<sup>1,3,4,5</sup> and Ira M. Hall<sup>1,3,5</sup>

<sup>1</sup>Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia 22903, USA; <sup>2</sup>Department of Computer Science, University of Virginia, Charlottesville, Virginia 22903, USA; <sup>3</sup>Center for Public Health Genomics, University of Virginia, Charlottesville, Virginia 22908, USA; <sup>4</sup>Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia 22908, USA

# 64 Tumors and 65 matched normals (1 dup.)

The Cancer Genome Atlas

Understanding genomics to improve cancer care

- 12 breast invasive carcinomas (BRCA)
- 3 colon adenocarcinomas (COAD)
- 18 glioblastoma multiforme (GBM)
- 6 lung adenocarcinoma (LUAD)
- 13 lung squamous cell carcinoma (LUSC)
- 11 ovarian serous cystadenocarcinoma (OV)
- 2 rectum adenocarcinoma (READ)



# How do we assess the quality of the somatic rearrangement calls?



#### 64 tumor / normal pairs

# 2. Pooling yields accurate predictions of somatically-acquired SVs in tumors.





Assuming all normal-only calls are false, suggests 5% somatic prediction error rate. Likelihood of LOH suggests it is actually lower.

Thursday, July 25, 13

### Much worse if we just did a simple tumor/ normal comparison (the standard)





Somatic misclassification rate jumps from 5% with pooling to 86%!

Thursday, July 25, 13

We have a high-quality set of somatic rearrangements from multiple tumors.

But what do they tell us about chromosome evolution in cancers?

### **Observation 1.**

We immediately noticed several staggeringly complex rearrangements (CRs).

# A staggeringly complex variant

253/296 (85%) breakpoints in this tumor comprise a single complex rearrangement

red = deletion green = tandem duplication blue = inversion grey = inter-chromosomal

### Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development

Philip J. Stephens,<sup>1</sup> Chris D. Greenman,<sup>1</sup> Beiyuan Fu,<sup>1</sup> Fengtang Yang,<sup>1</sup> Graham R. Bignell,<sup>1</sup> Laura J. Mudie,<sup>1</sup> Erin D. Pleasance,<sup>1</sup> King Wai Lau,<sup>1</sup> David Beare,<sup>1</sup> Lucy A. Stebbings,<sup>1</sup> Stuart McLaren,<sup>1</sup> Meng-Lay Lin,<sup>1</sup> David J. McBride,<sup>1</sup> Ignacio Varela,<sup>1</sup> Serena Nik-Zainal,<sup>1</sup> Catherine Leroy,<sup>1</sup> Mingming Jia,<sup>1</sup> Andrew Menzies,<sup>1</sup> Adam P. Butler,<sup>1</sup> Jon W. Teague,<sup>1</sup> Michael A. Quail,<sup>1</sup> John Burton,<sup>1</sup> Harold Swerdlow,<sup>1</sup> Nigel P. Carter,<sup>1</sup> Laura A. Morsberger,<sup>2</sup> Christine Iacobuzio-Donahue,<sup>2</sup> George A. Follows,<sup>3</sup> Anthony R. Green,<sup>3,4</sup> Adrienne M. Flanagan,<sup>5,6</sup> Michael R. Stratton,<sup>1,7</sup> P. Andrew Futreal,<sup>1</sup> and Peter J. Campbell<sup>1,3,4,\*</sup>

# **Chromothripsis:** chromosome shattering in a single, catastrophic event.

# Why are complex genomic rearrangements important?

1) Punctuated genome evolution





# Why are complex genomic rearrangements important?

Punctuated genome evolution
Mechanistically interesting

# A model for chromothripis



Stephens et al., Cell, 2011

### Identifying complex rearrangements



### **Observation 2.**

# Complex rearrangements are quite common in tumor genomes.

25% of all somatic breakpoints are part of complex mutations. Not random.

	Breakpoints			Complex rearrangements	
	Total (mean)	% in clusters	% in CGRs	Mild (3-9 breaks)	Extreme (>9 breaks)
BRCA (n=12)	1657 (138)	4.2%	2.1%	11	0
COAD (n=3)	90 (30)	10%	4.4%	1	0
GBM (n=18)	1088 (60)	70%	49.3%	18	9 (7)
LUAD (n=6)	356 (59)	23%	16.8%	9	2 (2)
LUSC (n=13)	1806 (139)	26.7%	7.7%	27	2 (2)
OV (n=11)	1096 (100)	11.6%	4.8%	15	0
READ (n=2)	86 (43)	11.6%	11.6%	3	0
Total	6179	25%	13.6%	84	13 (11)

### **Observation 3.**

# Complex rearrangements are very common in glioblastoma.

Enrichment in GBM. Compare to BRCA: more breakpoints per sample, but rarely in complex loci

	Breakpoints			rearrangements	
	Total (mean)	% in clusters	% in CGRs	Mild (3-9 breaks)	Extreme (>9 breaks)
BRCA (n=12)	1657 (138)	4.2%	2.1%	11	0
COAD (n=3)	90 (30)	10%	4.4%	1	0
GBM (n=18)	1088 (60)	70%	49.3%	18	9 (7)
LUAD (n=6)	356 (59)	23%	16.8%	9	2 (2)
LUSC (n=13)	1806 (139)	26.7%	7.7%	27	2 (2)
OV (n=11)	1096 (100)	11.6%	4.8%	15	0
READ (n=2)	86 (43)	11.6%	11.6%	3	0

13.6%

84

13 (11)

25%

6179

**Total** 

# **Observation 4.**

# Vast architectural diversity observed for complex variants

Thursday, July 25, 13

#### Focal amplification of EGFR





# Chromothripis examples



### **Observation 5.**

Complex rearrangements have elevated intra-tumor allele frequencies

# Complex loci have higher allele frequencies



#### Allele Frequency

	<0.35	0.35-0.65	>0.65
simple	60.4%	34.5%	5%
complex	49.8%	45.6%	4.6%
complex <20	56.5%	39.6%	3.9%
complex >=20	44.1%	50.7%	5.2%

Thursday, July 25, 13

**Why?** Evidence that chromothriptic medulloblastomas form extrachromosomal circles (double minutes) containing oncogenes

#### Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with *TP*53 Mutations

Cell

Tobias Rausch,<sup>1,18</sup> David T.W. Jones,<sup>2,18</sup> Marc Zapatka,<sup>2,18</sup> Adrian M. Stütz,<sup>1,18</sup> Thomas Zichner,<sup>1</sup> Joachim Weischenfeldt,<sup>1</sup> Natalie Jäger,<sup>3</sup> Marc Remke,<sup>2,5</sup> David Shih,<sup>6</sup> Paul A. Northcott,<sup>6</sup> Elke Pfaff,<sup>2</sup> Jelena Tica,<sup>1</sup> Qi Wang,<sup>5</sup> Luca Massimi,<sup>7</sup> Hendrik Witt,<sup>2,5</sup> Sebastian Bender,<sup>2,5</sup> Sabrina Pleier,<sup>2,5</sup> Huriye Cin,<sup>2</sup> Cynthia Hawkins,<sup>6,8</sup> Christian Beck,<sup>5</sup> Andreas von Deimling,<sup>9</sup> Volkmar Hans,<sup>10</sup> Benedikt Brors,<sup>3</sup> Roland Eils,<sup>3,20</sup> Wolfram Scheurlen,<sup>11</sup> Jonathon Blake,<sup>1</sup> Vladimir Benes,<sup>1</sup> Andreas E. Kulozik,<sup>5</sup> Olaf Witt,<sup>5,4</sup> Dianna Martin,<sup>12</sup> Cindy Zhang,<sup>12</sup> Rinnat Porat,<sup>12</sup> Diana M. Merino,<sup>12</sup> Jonathan Wasserman,<sup>12</sup> Nada Jabado,<sup>13</sup> Adam Fontebasso,<sup>13</sup> Lars Bullinger,<sup>14</sup> Frank G. Rücker,<sup>14</sup> Konstanze Döhner,<sup>14</sup> Hartmut Döhner,<sup>14</sup> Jan Koster,<sup>15</sup> Jan J. Molenaar,<sup>15</sup> Rogier Versteeg,<sup>15</sup> Marcel Kool,<sup>2</sup> Uri Tabori,<sup>6,12</sup> David Malkin,<sup>12</sup> Andrey Korshunov,<sup>9</sup> Michael D. Taylor,<sup>6,16</sup> Peter Lichter,<sup>2,19,\*</sup> Stefan M. Pfister,<sup>2,5,19,\*</sup>

# Are brain tumors particularly prone to chromothripsis?

doi:10.1038/nature10910

#### Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

Jan J. Molenaar<sup>1</sup>\*, Jan Koster<sup>1</sup>\*, Danny A. Zwijnenburg<sup>1</sup>, Peter van Sluis<sup>1</sup>, Linda J. Valentijn<sup>1</sup>, Ida van der Ploeg<sup>1</sup>, Mohamed Hamdi<sup>1</sup>, Johan van Nes<sup>1</sup>, Bart A. Westerman<sup>1</sup>, Jennemiek van Arkel<sup>1</sup>, Marli E. Ebus<sup>1</sup>, Franciska Haneveld<sup>1</sup>, Arjan Lakeman<sup>1</sup>, Linda Schild<sup>1</sup>, Piet Molenaar<sup>1</sup>, Peter Stroeken<sup>1</sup>, Max M. van Noesel<sup>2</sup>, Ingrid Øra<sup>1,3</sup>, Evan E. Santo<sup>1</sup>, Huib N. Caron<sup>4</sup>, Ellen M. Westerhout<sup>1</sup> & Rogier Versteeg<sup>1</sup>

#### Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with *TP*53 Mutations



Tobias Rausch,<sup>1,18</sup> David T.W. Jones,<sup>2,18</sup> Marc Zapatka,<sup>2,18</sup> Adrian M. Stütz,<sup>1,18</sup> Thomas Zichner,<sup>1</sup> Joachim Weischenfeldt,<sup>1</sup> Natalie Jäger,<sup>3</sup> Marc Remke,<sup>2,5</sup> David Shih,<sup>6</sup> Paul A. Northcott,<sup>6</sup> Elke Pfaff,<sup>2</sup> Jelena Tica,<sup>1</sup> Qi Wang,<sup>5</sup> Luca Massimi,<sup>7</sup> Hendrik Witt,<sup>2,5</sup> Sebastian Bender,<sup>2,5</sup> Sabrina Pleier,<sup>2,5</sup> Huriye Cin,<sup>2</sup> Cynthia Hawkins,<sup>6,8</sup> Christian Beck,<sup>5</sup> Andreas von Deimling,<sup>9</sup> Volkmar Hans,<sup>10</sup> Benedikt Brors,<sup>3</sup> Roland Eils,<sup>3,20</sup> Wolfram Scheurlen,<sup>11</sup> Jonathon Blake,<sup>1</sup> Vladimir Benes,<sup>1</sup> Andreas E. Kulozik,<sup>5</sup> Olaf Witt,<sup>5,4</sup> Dianna Martin,<sup>12</sup> Cindy Zhang,<sup>12</sup> Rinnat Porat,<sup>12</sup> Diana M. Merino,<sup>12</sup> Jonathan Wasserman,<sup>12</sup> Nada Jabado,<sup>13</sup> Adam Fontebasso,<sup>13</sup> Lars Bullinger,<sup>14</sup> Frank G. Rücker,<sup>14</sup> Konstanze Döhner,<sup>14</sup> Hartmut Döhner,<sup>14</sup> Jan Koster,<sup>15</sup> Jan J. Molenaar,<sup>15</sup> Rogier Versteeg,<sup>15</sup> Marcel Kool,<sup>2</sup> Uri Tabori,<sup>6,12</sup> David Malkin,<sup>12</sup> Andrey Korshunov,<sup>9</sup> Michael D. Taylor,<sup>6,16</sup> Peter Lichter,<sup>2,19,\*</sup> Stefan M. Pfister,<sup>2,5,19,\*</sup>

- Stephens et al. (2011) estimated an incidence of 1.3% in all tumors, and perhaps 25% of bone cancers (by microarrays)
- Molenaar et al. (2012) estimated 11% of neuroblastoma samples (by sequencing)
- Rausch et al. (2012) estimated 13% of Medulloblastomas (by microarrays), strongly correlated with P53 loss.
- We find that 40-50% of GBM and LUSC samples have chromothripsis (by sequencing)



- Complex rearrangements are quite common in tumors.
- Many appear to be chromothripsis.
- 70% of glioblastomas have very complex rearrangements
- Fitness possibly conferred by oncogene amplification
- Origin? Prevalence? Clinical utility?

# Acknowledgements



#### Uma Paila, Ph.D.

Postdoctoral Research Associate

udp3f @ virginia.edu

**Research Projects and Interests:** Investigation of the genetic basis of extreme sensitivity to ionizing radiation; development of new analytical tools for exploring genetic variation identified through next-generation sequencing projects.



#### Neil Kindlon, M.S.

Staff Scientist and Software Engineer

nek3d @ virginia.edu

Research Projects and Interests: Software development for genomic analysis. Structural variation discovery and interpretation using DNA sequencing technologies.



#### Ryan Layer



rl6sf @ virginia.edu

**Research Interests:** Scalable algorithm development for high-throughput genomic analysis; genome data mining and analysis; structural variation discovery and interpretation.

### Ira Hall

Ankit Malhotra Michael Lindberg Royden Clark Svetlana Sokolova Mitchell Leibowitz Univ. of Virginia Univ. of Virginia Univ. of Virginia Univ. of Virginia Univ. of Virginia

#### Funding

NHGRI: R01 HG006693-01 NIEHS: R21 ES020521-01 UVA Fund for Excellence in Science and Tech. UVA Cancer Center Pilot Program